MHRA Findings Dissemination Joint Office Launch Jan Presented by: Carolyn Maloney UHL R&D Manager

Transcription

1 MHRA Findings Dissemination Joint Office Launch Jan Presented by: Carolyn Maloney UHL R&D Manager

2 Purpose of presentation To feed back abridged findings from March 2011 MHRA Statutory Systems Inspection To ensure all relevant parties are aware of expectations and responsibilities To promote the facilitative approach to the management of research at UoL & UHL

3 Pre-Inspection Dossier Comprehensive dossier detailing organisational maps Lists of all Medicinal Product studies Sponsored and Hosted Lists of all SOPs Pharmacovigilance SOP Policies & SOPs for IT, Medical Records, Pharmacy, Laboratories Overview of organisation A dossier folder is maintained annually at UHL. UoL encouraged to adopted same policy.

4 What was inspected? Safety Reporting / Pharmacovigilance Training Four studies 2 published & 2 actively recruiting RM&G Approval processes UHL & CLRN Monitoring & Audit processes (QC/QA) Pharmacy Archiving & Medical Records Quality management systems

5 Who was involved? 2 Inspectors over 4 days ( 2.5k per inspector per day!) Chairman was present at opening meeting Carolyn & Joanne managed the inspection The whole R&D Team & University Colleagues The RM&G Team from CLRN Pharmacy Medical Records CI & Study Teams for each of 4 studies Volunteer observers Volunteer scribes

6 Findings Three categories of findings: Critical can incur sanctions and require immediate resolution Major require action within time frame specified by institution Other noted and requires action.

7 Critical Findings There were no critical findings

8 Major Findings There were two Major findings: Informed Consent (1) Trial Management (2)

9 Major Findings (1) Consent Issues The MHRA were keen to point out that Consent issues were identified at the last inspection. The issues identified this time are different to those recorded in Consent issues were also identified in It is the view of UHL that all necessary steps must be taken to ensure that Consent issues are not identified for a fourth occasion which would be highly likely to incur a Critical Finding

10 Consent Issues identified Consent forms did not permit the Sponsor / NHS Trust & in one case the MHRA to access subject notes and / or data for the purpose of Monitoring / Audit Consent Forms initialled by research team member Consent Forms dated by research team member Subject names written by research team member Incorrect versions of forms used Subjects consented to participate before Trust Approval Consent form boxes ticked not initialled Patients given insufficient time to consider the study prior to consenting Incorrect version of PIS referenced on a consent form

11 Consent corrective action A review of all UHL / UoL Sponsored CTiMP study consent forms has been undertaken. Where consent forms did not allow appropriate access, a non substantial amendment has been mandated by the Sponsor 100% Audit of Consent forms for all UHL / UoL Studies has been introduced. A table of metrics has been designed to report progress to the Board on a ¼ly basis Risk of Critical Finding has been added to Datix potential of sanctions from MHRA if similar issues identified at next visit high serious implications for Trust acting as Sponsor and to reputation Consent Training required as part of corrective action where issues identified during future Audits / Monitoring SOP CLIN/102 Informed Consent revised and published

12 Trial Management (2) No procedures or processes for management of Healthy Volunteer Trials No process for confirming the volunteer identity No process for verification of relevant medical history for volunteers No process for preventing over volunteering A member of pharmacy staff recruited to a study dispensed their own IMP

13 Trial Management Corrective Action SOP CLIN/136 has been published and will be on the Website in due course. Includes requirement to register each participant on TOPs & to contact GP before commencing IMP Important to recognise that there are several types of Healthy volunteer studies active at UHL the SOP covers those dealing with ADME studies No individual named on the Delegation of Authority and Signature Log may participate in the research

14 Other findings 1-7 Slides included for your information While relatively minor individually and in the majority administrative, if these other findings are identified once more at another inspection it is highly likely that the finding will be escalated to Major Important to recognise and accept the level of attention to detail required when undertaking research particularly of IMP

15 Thank You Thank you for your attention Do you have any questions?

16 Other findings (1) Pharmacovigilance A Protocol was not explicit in relation to SAE reporting. Care must be taken to exclude relevant disease progression when writing Protocols There was no process for reporting and tracking pregnancy during Research The template for SAEs did not easily facilitate causality assessments nor expectedness Inconsistency in instruction via SOPs as to whether R&D or CI should report to MHRA / Ethics Incorrect SAE forms submitted to R&D

17 Other findings (1) Corrective Action SOP on Protocols revised & Sponsor review more robust to include discussion with CI about safety reporting Pregnancy reporting form published Revised Safety SOP published Revised SAE reporting form published Version control of documents added to Monitoring check list SOPs undergoing consistency check

18 Other findings (2) IMP Management Temperature deviations noted but not escalated Suitability assessment of remote storage to be carried out by Pharmacy and documented No signature on pharmacy accountability log for receipt of kits into pharmacy No receipt documentation for consignment received into Pharmacy to confirm received in good condition IMP kits receipted as in good condition but package had not been opened to check IMP still being stored in returns study closed in March 2010

19 Other findings (2) Corrective Action Pharmacy assessment for remote storage to be reviewed SOP for remote storage was revised prior to Inspection Monitoring of all studies with remote storage to be commenced Temperature monitoring to be added to the GCP training Research nurses responsible for temperature monitoring to undergo annual training Signature logs to be reviewed and updated SOPs for expired medication revised Delivery notes to be filed in Pharmacy files Reminder to all staff to remove outer packaging before signing acceptance of consignment Pharmacy archiving SOP 410 had not been followed Reminder to all staff to follow SOPs Discussion with PI at study close down ref. patient returns

20 Other findings (3) Quality Management Systems A user name and password for randomisation system clearly visible in the TMF No process for ensuring IB / SmPC reviewed annually

21 Other findings (3) Corrective Action Reminder about Passwords protection, IT Policies on electronic security to be added to GCP Training IB/SmPC updates added to CI Roles & responsibilities and an alert now added to the R&D Database

22 Other findings (4) TMF / Essential documents Inconsistencies between what the protocol says will happen during the study and what is written in IRAS Consent form stated notes to be viewed by Research Team, Regulatory Authorities and NHS Trust IRAS form stated only research nurses and researchers only Protocol exclusion criteria <18 & >85 years. CRF exclusion >18 and <85 Protocol stated adherence to a Trust SOP that did not exist Application stated that a department would oversee statistics at the Trust when no such department exists When documents stored electronically, they must be stored in a format that allows access by inspectors

23 Other findings (4) TMF / Essential documents Evidence of appropriate training for stats analysis not available for individual with delegated responsibility Stats analysis not included on the Delegation of Authority and Signature log Submissions to MHRA / REC not available in TMF File notes not signed or dated All entries on a Delegation of Authority and Signature Log dated on the same date, after the study had commenced. Therefore, no evidence that study related activity had been discussed with the team prior to study start

24 Other Findings (4) Corrective Action Consistency checking has been added to the Sponsor review process Initiation visits introduced to take place with the team and support services prior to first patient recruited

25 Other findings (5) Contracts & Agreements Contracts signed by CI and not by the authorised individuals on behalf of the Trust External provider contracts not present for Stats analysis with Universities nor for supply of IMP

26 Other findings (5) Corrective Action Added to the Sponsor review process. Contracts with external providers will be discussed as appropriate with the CI prior to any application submissions Reiterate that only authorised signatories on behalf of the Trust may sign

27 Other findings (6) Facilities No temperature monitoring had been performed for a -20 o c freezer

28 Other findings (6) Corrective action In future, where studies involve storage of samples in freezers, the freezers will be part of an existing monitoring programme (Icespy). Where this is not possible, appropriate action will be taken to include the freezer in the monitoring set up. Any additional costs for this will be borne by the research study budget

29 Other findings (7) Training No evidence of GCP Training for some staff within a study folder Lack of evidence of training for key study tasks e.g. stats analysis

30 Other findings (7) Corrective Action Valid GCP Certificates MUST be held within the TMF for ALL staff involved in the study named on the Delegation of Authority & Signature Log Evidence of relevant training specific to the study role e.g. Stats GCP Certificates are Valid for TWO years.

31 Since the inspection: The following issues have been identified since the MHRA Inspection Expired medication supplied to patient to take home medication did not hold expiry date on boxes Similar issues will be published on the new website when launched later this month